Variability of clopidogrel response in patients with type 2 diabetes mellitus (Q37936014)

25 August 2017

1 reference

title

Variability of clopidogrel response in patients with type 2 diabetes mellitus (English)

1 reference

25 August 2017

0 references

1 reference

2

Subhash Banerjee

1 reference

25 August 2017

3

Darren K McGuire

1 reference

25 August 2017

Hurst M Hall

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

Diabetes and Vascular Disease Research

25 August 2017

published in

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

245-253

1 reference

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Factors contributing to increased platelet reactivity in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Insulin, insulin resistance, and platelet signaling in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Effects of VLDL and remnant particles on platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Platelet dysfunction in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Role of mean platelet volume in triagging acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Aspirin and clopidogrel resistance: an emerging clinical entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Correlation between cardiovascular disease and diabetes mellitus: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164111420890

21 January 2018

Identifiers

DOI

10.1177/1479164111420890

1 reference

25 August 2017

1 reference